The Future of Mobile Health: Mobile Adoption, mHealth and Mobile Marketing

Manhattan ResearchGlobal pharmaceutical and healthcare market research company Manhattan Research releases its latest consumer marketing analysis titled "The Future of Mobile Health: Mobile Adoption, mHealth and Mobile Marketing" as part of its Cybercitizen Health™ v8.0 market research and strategic advisory service.

"The Future of Mobile Health" gives an in-depth look at the growing mHealth market, which now stands at over 10 million U.S. adults using mobile devices for health information, and contains market data, charts, and analysis for key demographic and condition-specific trends. It also discusses how companies are currently using mobile health applications, mobile marketing opportunities and strategies, and insight to where the market is heading.

According to the analysis, consumers with smartphones tend to be the most interested in mobile health applications for weight loss, as well as prescription drug tracking. The WebMD Mobile application for the iPhone, which provides information on every day health topics and on symptoms, drugs or treatments and basic first aid, has seen over 200,000 downloads since launching in November 2008. Johnson & Johnson also recently launched the CareConnector iPhone application as an accessory to its caregiver support site, StrengthForCaring.com.

"Mobile Health, or mHealth, is exploding around the globe, with programs for remote monitoring, disaster preparedness, treatment compliance, and education appearing in countries where traditional forms of communication, such as television, mail, or even the Internet, were not available," said Meredith Abreu Ressi, author of the analysis and Vice President of Research at Manhattan Research. "In the U.S., there are similar opportunities - along with the ability to explore mobile marketing initiatives such as mCoupons, opt-in text message databases, or short code DTC response. But developing content for the mobile Web has its own set of rules, so simply repurposing existing Web sites for mobile access is insufficient."

Analysis Outline
Title: The Future of Mobile Health: Mobile Adoption, mHealth, and Mobile Marketing

  • Mobile Adoption in the U.S.
  • mHealth and Mobile Marketing Today
    • mHealth in the U.S.
    • A Look Around the iPhone App Store
  • The Future of mHealth and Mobile Marketing
    • Benefits of Mobile Health Initiatives
    • Opportunities for Mobile Health (mHealth) in the U.S.
    • Mobile Marketing Opportunities
    • Key Learnings and Action Items

For an excerpt from the analysis and more information about its contents, please visit: http://www.manhattanresearch.com/products/Research_Modules/Consumer/future-of-mobile-health.aspx

Accessing the "The Future of Mobile Health" analysis is immediately available to subscribers of Manhattan Research's Cybercitizen Health™ v8.0 market research and strategic advisory service. For more information about becoming a subscriber to this service and gaining access to the in-depth consumer market data and analysis, visit http://www.manhattanresearch.com/cch.

About Cybercitizen Health™ v8.0
Cybercitizen Health™ v8.0 was fielded in Q3 2008 among 8,714 U.S. adults (ages 18+). This consumer market research and strategic advisory service focuses on how consumers use new media and technology for health and its impact on treatment and product decisions. For topics and available therapeutic segmentations (100+), please visit http://www.manhattanresearch.com/cch.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...